US-based biotechnology company Atreca has secured $35m in a series B financing round led by Wellington Management Company.

The funds will be utilised to progress the development of the company’s antibody-based therapeutics.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Calithera Biosciences has announced a public offering of common stock shares to raise up to $50m.

The US-based clinical-stage pharmaceutical company plans to use the funds towards general corporate purposes.

Spring Bank Pharmaceuticals plans to raise up to $50m through a public offering of shares of its common stock.

See Also:

"Spring Bank Pharmaceuticals plans to raise up to $50m through a public offering of shares of its common stock."

US-based clinical-stage biopharmaceutical company Spring Bank plans to use the proceeds for general corporate purposes.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Coherus BioSciences (formerly known as BioGenerics) has announced the private placement of six million shares of its common stock priced at $11.44 a share to raise $75m.

The company intends to raise a total of $150m in two tranches, with $75m to be raised in the first tranche.

The US-based biopharmaceutical company plans to use the funds towards the development of its pegfilgrastim biosimilar product candidate CHS-1701, as well as general corporate purposes.